CRDF is expected to report earnings to -25 cents per share on February 27
Q4'24
Est.
$-0.25
Q3'24
Beat
by $0.02
Q2'24
Missed
by $0.01
Q1'24
Beat
by $0.03
Q4'23
Beat
by $0.06
The last earnings report on November 07 showed earnings per share of -25 cents, beating the estimate of -27 cents. With 938.78K shares outstanding, the current market capitalization sits at 260.77M.
a cancer medicine oncology therapeutics company, which engages in the development of drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, lymphomas, and solid tumors